Carisma Therapeutics Stock Alpha and Beta Analysis
| CARM Stock | 0.85 0.01 1.19% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Carisma Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Carisma Therapeutics over a specified time horizon. Remember, high Carisma Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Carisma Therapeutics' market risk premium analysis include:
Beta 0.99 | Alpha (0.56) | Risk 2.75 | Sharpe Ratio (0.08) | Expected Return (0.22) |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Carisma |
Carisma Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Carisma Therapeutics market risk premium is the additional return an investor will receive from holding Carisma Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Carisma Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Carisma Therapeutics' performance over market.| α | -0.56 | β | 0.99 |
Carisma Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Carisma Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Carisma Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Carisma Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Carisma Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Carisma Therapeutics shares will generate the highest return on investment. By understating and applying Carisma Therapeutics stock market price indicators, traders can identify Carisma Therapeutics position entry and exit signals to maximize returns.
Carisma Therapeutics Return and Market Media
The median price of Carisma Therapeutics for the period between Tue, Sep 3, 2024 and Mon, Dec 2, 2024 is 0.98 with a coefficient of variation of 6.82. The daily time series for the period is distributed with a sample standard deviation of 0.07, arithmetic mean of 0.97, and mean deviation of 0.05. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Moderna, Carisma name autoimmune targets | 09/10/2024 |
2 | Importers now benefiting from new accounting system for the collection of duties and taxes for commercial goods | 10/21/2024 |
3 | Insider Trading | 10/31/2024 |
4 | Carisma Therapeutics Upgraded to Strong-Buy at EF Hutton Acquisition Co. I | 11/01/2024 |
5 | CARISMA Therapeutics Inc Reports Q3 2024 Revenue of 3.39M and GAAP EPS of -0. ... | 11/07/2024 |
6 | Carisma Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference | 11/27/2024 |
About Carisma Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Carisma or other stocks. Alpha measures the amount that position in Carisma Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2023 | 2024 (projected) | Interest Debt Per Share | 0.0577 | 0.0548 | Revenue Per Share | 0.45 | 0.42 |
Carisma Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Carisma Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Carisma Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Carisma Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Carisma Therapeutics. Please utilize our Beneish M Score to check the likelihood of Carisma Therapeutics' management manipulating its earnings.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Carisma Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Carisma Therapeutics Backtesting, Carisma Therapeutics Valuation, Carisma Therapeutics Correlation, Carisma Therapeutics Hype Analysis, Carisma Therapeutics Volatility, Carisma Therapeutics History and analyze Carisma Therapeutics Performance. To learn how to invest in Carisma Stock, please use our How to Invest in Carisma Therapeutics guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Carisma Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.